Latigo Reports Positive Phase IIb Data for Non-Opioid Acute Pain Candidate

LTG-001 achieved the primary endpoint of the Phase IIb LTG-001-010 trial (NCT07102459) by achieving better-than-placebo scores in the time-weighted sum of the pain-intensity difference (SPID) over the 48-hour treatment period (SPID48), based on the 0-10 range of scores of the Numeric Pain Rating Scale, with higher SPID48 values indicating greater pain reduction.

The post Latigo Reports Positive Phase IIb Data for Non-Opioid Acute Pain Candidate appeared first on GEN - Genetic Engineering and Biotechnology News.